160 related articles for article (PubMed ID: 22643560)
1. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R; Siegel E; Makhoul I; Williamson S
Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
J Clin Oncol; 2005 Sep; 23(27):6657-63. PubMed ID: 16170173
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
Thomas MB; Morris JS; Chadha R; Iwasaki M; Kaur H; Lin E; Kaseb A; Glover K; Davila M; Abbruzzese J
J Clin Oncol; 2009 Feb; 27(6):843-50. PubMed ID: 19139433
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
7. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Hainsworth JD; Spigel DR; Thompson DS; Murphy PB; Lane CM; Waterhouse DM; Naot Y; Greco FA
Oncologist; 2009 Dec; 14(12):1189-97. PubMed ID: 19965914
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.
Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S
Oncology; 2013; 84(1):32-8. PubMed ID: 23076239
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J; Park JO; Kim WS; Park SH; Park KW; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Joh J; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Park K
Cancer Chemother Pharmacol; 2004 Nov; 54(5):385-90. PubMed ID: 15248028
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE; Park JO; Lee J; Park YS; Park SH; Yoo BC; Paik SW; Koh KC; Kang WK; Lim HY
Cancer Chemother Pharmacol; 2009 Apr; 63(5):929-35. PubMed ID: 18726098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.
Kaseb AO; Garrett-Mayer E; Morris JS; Xiao L; Lin E; Onicescu G; Hassan MM; Hassabo HM; Iwasaki M; Deaton FL; Abbruzzese JL; Thomas MB
Oncology; 2012; 82(2):67-74. PubMed ID: 22327795
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Thomas MB; Chadha R; Glover K; Wang X; Morris J; Brown T; Rashid A; Dancey J; Abbruzzese JL
Cancer; 2007 Sep; 110(5):1059-67. PubMed ID: 17623837
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
Yen Y; Lim DW; Chung V; Morgan RJ; Leong LA; Shibata SI; Wagman LD; Marx H; Chu PG; Longmate JA; Lenz HJ; Ramanathan RK; Belani CP; Gandara DR
Am J Clin Oncol; 2008 Aug; 31(4):317-22. PubMed ID: 18845988
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
18. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Kim JW; Lee JO; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
Am J Clin Oncol; 2011 Apr; 34(2):125-9. PubMed ID: 20308869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
